A compound of Formula or a tautomer or a stereoisomeric form thereof, wherein X 1 represents (a-1) or (a-2): wherein 'a' and 'b' indicate how variable X 1 is attached to the remainder of the molecule; R 1 represents hydrogen; methyl; or C 2-6 alkyl optionally substituted with one substituent selected from the group consisting of Het 1, -OR 3, and -NR 4a R 4b; X represents -O- or -CH 2 -; in case X represents -CH 2 -: R z represents -O-C 1-4 alkyl optionally substituted with one substituent selected from the group consisting of -OR 5, -NR 6a R 6b, Ar 1, and Het 2; or R z is taken together with R 1 of (a-2), so that R z together with the atoms to which it is attached and (a-2) forms a bicyclic ring of formula (b-1) or (b-2): in case X represents -O-: R z represents C 2-4 alkenyl or C 1-4 alkyl, wherein said C 2-4 alkenyl or C 1-4 alkyl is optionally substituted with one substituent selected from the group consisting of -OR 5, -NR 6a R 6b, Ar 1, and Het 2; Het 1 represents morpholinyl, N-methylpiperazinyl, or tetrahydropyranyl; R 3 represents hydrogen, C 1-4 alkyl, or -C 2-4 alkyl-O-C 1-4 alkyl; R 4a and R 4b are each independently selected from the group consisting of hydrogen and C 1-4 alkyl; X 2 represents which can be attached to the remainder of the molecule in both directions; R 2 represents hydrogen; methyl; or C 2-6 alkyl optionally substituted with one substituent selected from the group consisting of Het 1, -OR 3, and -NR 4a R 4b; Het 2 represents morpholinyl or N-methylpiperazinyl; Ar 1 represents phenyl optionally substituted with one -O-C 1-4 alkyl; R y represents hydrogen or halo; R 5 represents hydrogen, C 1-4 alkyl, or -C 2-4 alkyl-O-C 1-4 alkyl; R 6a and R 6b are each independently selected from the group consisting of hydrogen and C 1-4 alkyl; R 7 represents hydrogen, C 1-4 alkyl, or -C 2-4 alkyl-O-C 1-4 alkyl; n is 1 or 2; m is 2; or a pharmaceutically acceptable salt, or a solvate thereof. wherein 'a' and 'b' indicate how variable X 1 is attached to the remainder of the molecule; R 1 represents hydrogen; methyl; or C 2-6 alkyl optionally substituted with one substituent selected from the group consisting of Het 1, -OR 3, and -NR 4a R 4b; X represents -O- or -CH 2 -; in case X represents -CH 2 -: R z represents -O-C 1-4 alkyl optionally substituted with one substituent selected from the group consisting of -OR 5, -NR 6a R 6b, Ar 1, and Het 2; or R z is taken together with R 1 of (a-2), so that R z together with the atoms to which it is attached and (a-2) forms a bicyclic ring of formula (b-1) or (b-2): in case X represents -O-: R z represents C 2-4 alkenyl or C 1-4 alkyl, wherein said C 2-4 alkenyl or C 1-4 alkyl is optionally substituted with one substituent selected from the group consisting of -OR 5, -NR 6a R 6b, Ar 1, and Het 2; Het 1 represents morpholinyl, N-methylpiperazinyl, or tetrahydropyranyl; R 3 represents hydrogen, C 1-4 alkyl, or -C 2-4 alkyl-O-C 1-4 alkyl; R 4a and R 4b are each independently selected from the group consisting of hydrogen and C 1-4 alkyl; X 2 represents which can be attached to the remainder of the molecule in both directions; R 2 represents hydrogen; methyl; or C 2-6 alkyl optionally substituted with one substituent selected from the group consisting of Het 1, -OR 3, and -NR 4a R 4b; Het 2 represents morpholinyl or N-methylpiperazinyl; Ar 1 represents phenyl optionally substituted with one -O-C 1-4 alkyl; R y represents hydrogen or halo; R 5 represents hydrogen, C 1-4 alkyl, or -C 2-4 alkyl-O-C 1-4 alkyl; R 6a and R 6b are each independently selected from the group consisting of hydrogen and C 1-4 alkyl; R 7 represents hydrogen, C 1-4 alkyl, or -C 2-4 alkyl-O-C 1-4 alkyl; n is 1 or 2; m is 2; or a pharmaceutically acceptable salt, or a solvate thereof. R z represents C 2-4 alkenyl or C 1-4 alkyl, wherein said C 2-4 alkenyl or C 1-4 alkyl is optionally substituted with one substituent selected from the group consisting of -OR 5, -NR 6a R 6b, Ar 1, and Het 2; Het 1 represents morpholinyl, N-methylpiperazinyl, or tetrahydropyranyl; R 3 represents hydrogen, C 1-4 alkyl, or -C 2-4 alkyl-O-C 1-4 alkyl; R 4a and R 4b are each independently selected from the group consisting of hydrogen and C 1-4 alkyl; X 2 represents which can be attached to the remainder of the molecule in both directions; R 2 represents hydrogen; methyl; or C 2-6 alkyl optionally substituted with one substituent selected from the group consisting of Het 1, -OR 3, and -NR 4a R 4b; Het 2 represents morpholinyl or N-methylpiperazinyl; Ar 1 represents phenyl optionally substituted with one -O-C 1-4 alkyl; R y represents hydrogen or halo; R 5 represents hydrogen, C 1-4 alkyl, or -C 2-4 alkyl-O-C 1-4 alkyl; R 6a and R 6b are each independently selected from the group consisting of hydrogen and C 1-4 alkyl; R 7 represents hydrogen, C 1-4 alkyl, or -C 2-4 alkyl-O-C 1-4 alkyl; n is 1 or 2; m is 2; or a pharmaceutically acceptable salt, or a solvate thereof.